vs
Alkermes plc.（ALKS）与Rapid7, Inc.（RPD）财务数据对比。点击上方公司名可切换其他公司
Alkermes plc.的季度营收约是Rapid7, Inc.的1.8倍（$384.5M vs $217.4M），Alkermes plc.净利率更高（12.8% vs 1.4%，领先11.4%），Rapid7, Inc.同比增速更快（0.5% vs -10.6%），Alkermes plc.自由现金流更多（$170.0M vs $36.4M），过去两年Alkermes plc.的营收复合增速更高（4.8% vs 3.0%）
Alkermes plc是一家全产业链布局的生物制药企业，专注于精神障碍与神经系统疾病相关药物的研发。公司1987年由迈克尔·沃尔创立，2011年9月与原Élan集团旗下的药物制剂及生产部门Elan Drug Technologies合并，总部位于都柏林，在马萨诸塞州沃尔瑟姆设有研发中心，俄亥俄州威尔明顿建有生产基地。
Rapid7是全球领先的网络安全企业，提供漏洞管理、威胁检测与响应、云安全、安全分析等全系列安全解决方案，服务全球科技、医疗、金融、制造等行业的各类规模企业及公共部门客户，助力客户高效识别、应对和缓解网络安全风险。
ALKS vs RPD — 直观对比
营收规模更大
ALKS
是对方的1.8倍
$217.4M
营收增速更快
RPD
高出11.1%
-10.6%
净利率更高
ALKS
高出11.4%
1.4%
自由现金流更多
ALKS
多$133.6M
$36.4M
两年增速更快
ALKS
近两年复合增速
3.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $384.5M | $217.4M |
| 净利润 | $49.3M | $3.1M |
| 毛利率 | 88.0% | 68.9% |
| 营业利润率 | 15.1% | 1.0% |
| 净利率 | 12.8% | 1.4% |
| 营收同比 | -10.6% | 0.5% |
| 净利润同比 | -66.3% | 44.1% |
| 每股收益（稀释后） | $0.29 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALKSRPD
| Q4 25 | $384.5M | $217.4M | ||
| Q3 25 | $394.2M | $218.0M | ||
| Q2 25 | $390.7M | $214.2M | ||
| Q1 25 | $306.5M | $210.3M | ||
| Q4 24 | $430.0M | $216.3M | ||
| Q3 24 | $378.1M | $214.7M | ||
| Q2 24 | $399.1M | $208.0M | ||
| Q1 24 | $350.4M | $205.1M |
净利润ALKSRPD
| Q4 25 | $49.3M | $3.1M | ||
| Q3 25 | $82.8M | $9.8M | ||
| Q2 25 | $87.1M | $8.3M | ||
| Q1 25 | $22.5M | $2.1M | ||
| Q4 24 | $146.5M | $2.2M | ||
| Q3 24 | $92.4M | $15.4M | ||
| Q2 24 | $91.4M | $6.5M | ||
| Q1 24 | $36.8M | $1.4M |
毛利率ALKSRPD
| Q4 25 | 88.0% | 68.9% | ||
| Q3 25 | 86.9% | 70.2% | ||
| Q2 25 | 87.3% | 70.6% | ||
| Q1 25 | 83.9% | 71.7% | ||
| Q4 24 | 85.6% | 69.5% | ||
| Q3 24 | 83.3% | 70.6% | ||
| Q2 24 | 84.6% | 70.7% | ||
| Q1 24 | 83.3% | 70.3% |
营业利润率ALKSRPD
| Q4 25 | 15.1% | 1.0% | ||
| Q3 25 | 22.6% | 2.7% | ||
| Q2 25 | 23.8% | 1.6% | ||
| Q1 25 | 4.5% | -0.0% | ||
| Q4 24 | 37.8% | 3.4% | ||
| Q3 24 | 27.7% | 6.0% | ||
| Q2 24 | 27.5% | 2.5% | ||
| Q1 24 | 12.4% | 4.7% |
净利率ALKSRPD
| Q4 25 | 12.8% | 1.4% | ||
| Q3 25 | 21.0% | 4.5% | ||
| Q2 25 | 22.3% | 3.9% | ||
| Q1 25 | 7.3% | 1.0% | ||
| Q4 24 | 34.1% | 1.0% | ||
| Q3 24 | 24.4% | 7.2% | ||
| Q2 24 | 22.9% | 3.1% | ||
| Q1 24 | 10.5% | 0.7% |
每股收益（稀释后）ALKSRPD
| Q4 25 | $0.29 | $0.05 | ||
| Q3 25 | $0.49 | $0.15 | ||
| Q2 25 | $0.52 | $0.13 | ||
| Q1 25 | $0.13 | $0.03 | ||
| Q4 24 | $0.88 | $0.08 | ||
| Q3 24 | $0.55 | $0.21 | ||
| Q2 24 | $0.53 | $0.09 | ||
| Q1 24 | $0.21 | $0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $388.6M | $474.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.8B | $154.7M |
| 总资产 | $2.5B | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ALKSRPD
| Q4 25 | $388.6M | $474.7M | ||
| Q3 25 | $616.4M | $407.1M | ||
| Q2 25 | $521.2M | $511.7M | ||
| Q1 25 | $399.8M | $493.5M | ||
| Q4 24 | $291.1M | $521.7M | ||
| Q3 24 | $396.3M | $443.7M | ||
| Q2 24 | $535.1M | $442.6M | ||
| Q1 24 | $420.8M | $411.7M |
股东权益ALKSRPD
| Q4 25 | $1.8B | $154.7M | ||
| Q3 25 | $1.7B | $127.2M | ||
| Q2 25 | $1.6B | $90.4M | ||
| Q1 25 | $1.5B | $52.7M | ||
| Q4 24 | $1.5B | $17.7M | ||
| Q3 24 | $1.3B | $-5.1M | ||
| Q2 24 | $1.3B | $-52.6M | ||
| Q1 24 | $1.3B | $-86.4M |
总资产ALKSRPD
| Q4 25 | $2.5B | $1.7B | ||
| Q3 25 | $2.3B | $1.7B | ||
| Q2 25 | $2.3B | $1.6B | ||
| Q1 25 | $2.1B | $1.6B | ||
| Q4 24 | $2.1B | $1.7B | ||
| Q3 24 | $2.2B | $1.6B | ||
| Q2 24 | $2.2B | $1.5B | ||
| Q1 24 | $2.1B | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $170.1M | $37.6M |
| 自由现金流经营现金流 - 资本支出 | $170.0M | $36.4M |
| 自由现金流率自由现金流/营收 | 44.2% | 16.8% |
| 资本支出强度资本支出/营收 | 0.0% | 0.5% |
| 现金转化率经营现金流/净利润 | 3.45× | 12.01× |
| 过去12个月自由现金流最近4个季度 | $480.3M | $146.2M |
8季度趋势，按日历期对齐
经营现金流ALKSRPD
| Q4 25 | $170.1M | $37.6M | ||
| Q3 25 | $101.7M | $39.0M | ||
| Q2 25 | $150.2M | $47.5M | ||
| Q1 25 | $98.8M | $29.8M | ||
| Q4 24 | $190.4M | $63.8M | ||
| Q3 24 | $81.6M | $44.0M | ||
| Q2 24 | $146.0M | $32.9M | ||
| Q1 24 | $21.1M | $31.1M |
自由现金流ALKSRPD
| Q4 25 | $170.0M | $36.4M | ||
| Q3 25 | $84.4M | $34.8M | ||
| Q2 25 | $137.2M | $46.6M | ||
| Q1 25 | $88.7M | $28.4M | ||
| Q4 24 | $180.6M | $62.6M | ||
| Q3 24 | $73.3M | $42.6M | ||
| Q2 24 | $138.9M | $32.6M | ||
| Q1 24 | $12.8M | $30.4M |
自由现金流率ALKSRPD
| Q4 25 | 44.2% | 16.8% | ||
| Q3 25 | 21.4% | 16.0% | ||
| Q2 25 | 35.1% | 21.8% | ||
| Q1 25 | 28.9% | 13.5% | ||
| Q4 24 | 42.0% | 28.9% | ||
| Q3 24 | 19.4% | 19.9% | ||
| Q2 24 | 34.8% | 15.7% | ||
| Q1 24 | 3.6% | 14.8% |
资本支出强度ALKSRPD
| Q4 25 | 0.0% | 0.5% | ||
| Q3 25 | 4.4% | 1.9% | ||
| Q2 25 | 3.3% | 0.4% | ||
| Q1 25 | 3.3% | 0.6% | ||
| Q4 24 | 2.3% | 0.5% | ||
| Q3 24 | 2.2% | 0.6% | ||
| Q2 24 | 1.8% | 0.1% | ||
| Q1 24 | 2.4% | 0.3% |
现金转化率ALKSRPD
| Q4 25 | 3.45× | 12.01× | ||
| Q3 25 | 1.23× | 3.97× | ||
| Q2 25 | 1.72× | 5.70× | ||
| Q1 25 | 4.40× | 14.14× | ||
| Q4 24 | 1.30× | 29.36× | ||
| Q3 24 | 0.88× | 2.85× | ||
| Q2 24 | 1.60× | 5.03× | ||
| Q1 24 | 0.57× | 22.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALKS
| Vivitrol | $124.1M | 32% |
| Aristada And Aristada Initio | $97.2M | 25% |
| LYBALVI | $94.1M | 24% |
| Royalty | $65.7M | 17% |
| Manufacturing Revenue | $3.3M | 1% |
RPD
| Products | $209.1M | 96% |
| Services | $8.2M | 4% |
